You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

REDIRECTED AUTOLOGOUS CART- 19 T-CELL IMMUNOTHERAPY

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

FDG-PET/CT Imaging as Early Predictor of DP

Completed
  • Lymphoma
  • There is no intervention
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Mar 7, 2022

Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,

Not yet recruiting
  • Kidney Transplant
  • +2 more
  • Boston, Massachusetts
  • +2 more
Sep 20, 2023

Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL, Infants With Very High Risk KMT2A B-ALL, Patients With CNS

Active, not recruiting
  • Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL
  • +2 more
  • Murine CART19
  • Philadelphia, Pennsylvania
    Children's Hospital of Philadelphia
Jan 11, 2022

Multiple Myeloma Trial in Philadelphia (CART-19 cells)

Terminated
Has Results
  • Multiple Myeloma
  • CART-19 cells
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jan 4, 2023

B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma Trial in Philadelphia (Autologous, humanized anti-CD22 CAR

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • B Lineage Lymphoblastic Lymphoma
  • Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
  • Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
  • Philadelphia, Pennsylvania
    Children's Hospital of Philadelphia
Jan 25, 2023

B Cell Leukemias, B Cell Lymphomas Trial in Philadelphia (CART22 cells transduced with a lentiviral vector to express anti-CD22

Recruiting
  • B Cell Leukemias
  • B Cell Lymphomas
  • CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB
  • Philadelphia, Pennsylvania
    Children's Hospital of Philadelphia
Jan 19, 2022

B-cell Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma Trial in Aurora (CD19CAR-CD3Zeta-4-1BB-Expressing Autologous

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • B-cell Non Hodgkin Lymphoma
  • CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
  • Aurora, Colorado
    Children's Hospital Colorado
Nov 9, 2022

Chemo Resistant Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia Trial in Philadelphia (CART22-65s cells,

Active, not recruiting
  • Chemotherapy Resistant Acute Lymphoblastic Leukemia
  • Refractory Acute Lymphoblastic Leukemia
  • CART22-65s cells
  • huCART19 Cells
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Feb 18, 2022

Leukemia, Lymphoma, Cardiotoxicity Trial in Philadelphia

Completed
  • Leukemia
  • +4 more
    • Philadelphia, Pennsylvania
      Abramson Cancer Center of the University of Pennsylvania
    Jan 19, 2023

    Leukemia, Acute Lymphoblastic, Lymphoma, Non-Hodgkin Trial in Ribeirao Preto (CART-19)

    Not yet recruiting
    • Leukemia, Acute Lymphoblastic
    • Lymphoma, Non-Hodgkin
    • CART-19
    • Ribeirao Preto, Sao Paulo, Brazil
      Ribeirao Preto School of Medicine, University of Sao Paulo
    Oct 23, 2023

    Non-hodgkin Lymphoma,B Cell Trial in Beijing (Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide)

    Recruiting
    • Non-hodgkin Lymphoma,B Cell
    • Autologous CD19-STAR-T cell
    • +2 more
    • Beijing, Beijing, China
    • +1 more
    Nov 21, 2022

    Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Chronic Lymphocytic Leukemia Trial in Milwaukee (CAR-20/19-T cells (1.0 x10^5

    Completed
    Has Results
    • Lymphoma, Non-Hodgkin
    • +3 more
    • CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)
    • +3 more
    • Milwaukee, Wisconsin
      Froedtert Hospital & Medical College of Wisconsin
    Jun 26, 2022

    Acute Lymphocytic Leukemia, Diffuse Large Cell Lymphoma Trial in Philadelphia (huCART19)

    Completed
    • Acute Lymphocytic Leukemia
    • Diffuse Large Cell Lymphoma
    • huCART19
    • Philadelphia, Pennsylvania
      Children's Hospital of Philadelphia
    Sep 22, 2021

    B-cell Lymphoma Trial in Xuzhou (ASCT+CAR-T Cell Infusion)

    Recruiting
    • B-cell Lymphoma
    • ASCT+CAR-T Cell Infusion
    • Xuzhou, Jiangsu, China
      The Affiliated Hospital of Xuzhou Medical University
    Feb 23, 2023

    DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

    Not yet recruiting
    • Diffuse Large B-Cell Lymphoma
    • +6 more
    • Axicabtagene Ciloleucel
    • +10 more
    • (no location specified)
    Jan 13, 2023

    B-cell Lymphoma Trial in Hangzhou (PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells)

    Active, not recruiting
    • B-cell Lymphoma
    • PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital, Zhejiang University School of Med
    Sep 28, 2022

    Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia

    Recruiting
    • Acute Lymphoblastic Leukemia, in Relapse
    • +5 more
    • CAR-20/19-T cells (1 x 10^5 CAR-20/19-T cells/kg)
    • +4 more
    • Milwaukee, Wisconsin
      Medical College of Wisconsin
    Sep 22, 2022

    Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited Trial in Zhengzhou (ThisCART19A, Fludarabine Pill, Cyclophosphamide)

    Not yet recruiting
    • Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
    • Zhengzhou, Henan, China
      Henan cancer hospital
    Nov 28, 2022

    Recurrent Glioblastoma Trial in Beijing (Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous

    Not yet recruiting
    • Recurrent Glioblastoma
    • Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous T-lymphocytes.
    • Beijing, Beijing, China
      Beijing Tiantan Hospital
    Oct 10, 2022

    CD 19+ Acute Leukemia Trial in Seattle (T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC))

    Active, not recruiting
    • CD 19+ Acute Leukemia
    • T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)
    • Seattle, Washington
      Seattle Children's Hospital
    Mar 22, 2022

    Leukemia, Acute Lymphoblastic Leukemia Trial in New York (gene-modified T cells targeted)

    Active, not recruiting
    • Leukemia
    • Acute Lymphoblastic Leukemia
    • gene-modified T cells targeted
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Feb 1, 2023

    Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia in Children Trial in Singapore (Phase

    Recruiting
    • Lymphoblastic Leukemia
    • +4 more
    • Phase I
    • Phase II
    • Singapore, Singapore
      KK Women's and Children's hospital
    Jun 20, 2022

    B Cell Leukemia Trial in Seattle (Autologous CD19 CAR+ EGFTt + T cells)

    Active, not recruiting
    • B Cell Leukemia
    • Autologous CD19 CAR+ EGFTt + T cells
    • Seattle, Washington
      Seattle Children's Hospital
    Feb 15, 2022

    B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,

    Recruiting
    • B-Cell Non-Hodgkin Lymphoma
    • +7 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Dec 9, 2022

    Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

    Not yet recruiting
    • Multiple Sclerosis
    • +2 more
    • KYV-101 anti-CD19 CAR-T cell therapy
    • Standard lymphodepletion regimen
    • Palo Alto, California
      Stanford Multiple Sclerosis Center
    Nov 13, 2023